Previously, we detected ALK-mutant L1196M and EMT in a single crizotinib-resistant lesion from a patient with ALK-rearranged NSCLC13, indicating that these are concomitant mechanisms that can independently induce crizotinib resistance in patients with ALK-rearranged NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.